
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp's continued advancement of its orphan lung pipeline positions the company for long-term diversification and growth, enhancing its overall value proposition. The company's strategic focus on education and marketing initiatives is expected to boost the uptake of its products, particularly Afrezza and Tyvaso DPI, which have established strong market positions in diabetes and pulmonary arterial hypertension, respectively. Additionally, the promising developments regarding Furoscix and potential approvals for the auto-injector highlight significant future revenue drivers, further supporting a positive outlook for MannKind’s financial performance.
Bears say
MannKind Corp's stock faces a negative outlook primarily due to the announcement of a competitive product by SQ Innovation, which has been linked to a significant decline in share price, highlighting the potential vulnerability of MannKind's market position. Additionally, challenges such as potential lapses in intellectual property protection and adverse regulatory outcomes could further complicate the company’s commercialization efforts and limit its market potential. Finally, the presence of well-capitalized competitors with established products threatens MannKind's ability to maintain pricing power and could lead to further erosion of market share.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares